Asahi Kasei regains naftopidil rights
This article was originally published in Scrip
Executive Summary
Japan's Asahi Kasei Pharma has regained the rights to certain intellectual property relating to its alpha1-antagonist naftopidil from Roche Diagnostics. The financial terms of the transaction were not disclosed. Asahi Kasei markets various formulations of the product in Japan as Flivas for the treatment of benign prostatic hyperplasia, and said it was looking to expand both domestic and overseas sales. It expects Japanese sales of the product to reach ¥9.8 billion ($100.9 million) this fiscal year and has begun Phase II trials for the additional indication of neurogenic bladder.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.